FAT1 and fatty liver disease: While both models exhibited a reduction in the ω-6/ω-3 ratio, ω-3 PUFA supplementation led to a greater improvement of hepatic steatosis and inflammatory lipid mediator profile, compared with endogenous production in Fat-1 mice.